Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30126% above fair value
$21.89−0.22 (-1.00%)
Close on Nov 18, 2026Market cap $3.69BP/E –Yield –
Tango Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Tango Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $53.81M, up 121.5% year over year. For fiscal 2025 it was $62.38M, up 48.3% from the year before. The highest annual figure on record is $62.38M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.38M | +48.3% |
| FY2024 | Dec 31, 2024 | $42.07M | +15.2% |
| FY2023 | Dec 31, 2023 | $36.53M | +46.9% |
| FY2022 | Dec 31, 2022 | $24.86M | -32.9% |
| FY2021 | Dec 31, 2021 | $37.04M | +383.8% |
| FY2020 | Dec 31, 2020 | $7.66M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $53.81M | +363.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.18M | -84.0% |
| Q1 FY2025 | Mar 31, 2025 | $5.39M | -16.7% |
| Q4 FY2024 | Dec 31, 2024 | $4.12M | -24.2% |
| Q3 FY2024 | Sep 30, 2024 | $11.61M | +8.2% |
| Q2 FY2024 | Jun 30, 2024 | $19.88M | +36.1% |
| Q1 FY2024 | Mar 31, 2024 | $6.47M | +12.2% |
| Q4 FY2023 | Dec 31, 2023 | $5.43M | -15.3% |
| Q3 FY2023 | Sep 30, 2023 | $10.73M | +55.1% |
| Q2 FY2023 | Jun 30, 2023 | $14.60M | +153.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.77M | +0.1% |
| Q4 FY2022 | Dec 31, 2022 | $6.41M | +12.2% |
| Q3 FY2022 | Sep 30, 2022 | $6.92M | +2.0% |
| Q2 FY2022 | Jun 30, 2022 | $5.77M | -68.2% |
| Q1 FY2022 | Mar 31, 2022 | $5.76M | -9.8% |
| Q4 FY2021 | Dec 31, 2021 | $5.72M | -37.5% |
| Q3 FY2021 | Sep 30, 2021 | $6.79M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.15M | – |
| Q1 FY2021 | Mar 31, 2021 | $6.39M | – |
| Q4 FY2020 | Dec 31, 2020 | $9.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.26M | – |
See a number that looks wrong?